Analysts emphasize that "ESPR stock price" could re-rate higher if revenue beats by more than 5% in the upcoming quarter, which would signal stronger-than-expected product adoption rates. In the past 60 days, estimates for CRISPR Therapeutics’ 2024 loss per share have narrowed from $5.58 to $5.55. Loss per share estimates for 2025 have narrowed from $4.98 to $4.94 during the same time. Year to date, shares of CRSP have decreased 19%. To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. "ESPR stock price" volatility levels dropped by 6% after steady institutional accumulation, signaling reduced downside risk in the near term.